-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: sunshine
On December 8, the CDE official website showed that the application for the clinical trial of BeiGene’s TYK2 allosteric inhibitor BGB-23339 was accepted
Tyrosine kinase 2 (TYK2), a member of the JAK kinase family, functions as a key regulator of cytokine signaling pathways in a variety of immune-mediated diseases
BGB-23339 is a potent, highly selective, investigational TYK2 allosteric inhibitor currently in clinical development, targeting the regulatory pseudokinase (JH2) domain of TYK2
Many domestic and foreign pharmaceutical companies have already started to deploy TYK2 targets
BMS’s emphasis on TYK2 targets is obvious.
Domestic Nuocheng Jianhua, BeiGene, Haisco, and Microchip also have TYK2 targeted drugs under development